Grossman William purchased $10K of ENGN

Grossman William (Interim Chief Medical Officer) purchased 5,102 shares of enGene Therapeutics Inc. (ENGN) at $1.97 on 2026-09-22.

Original reporting
SEC EDGAR · Grossman William
Published Sep 24, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ENGN
Bullish
medium confidence
Mentioned
$ENGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENGNBullishLow
01

Why it matters

The insider buy adds a modest positive signal but is unlikely to move the stock significantly.

02

Market read

A routine insider purchase with minimal material impact; useful for tracking insider activity but not a strong trade catalyst.

03

What to watch

Potential upcoming clinical data releases could be the real driver of future price moves.

Relevance 4/10Novelty 5/10Timing: post‑market 2026‑09‑22

Background

Form 4 filings disclose insider trades; small purchases are common and often have limited market impact.

Company-level read

Ticker impact

$ENGNBullishMedium confidence
Context

Interim CMO Grossman William purchased 5,102 shares of ENGN for $10,050 in an open‑market transaction.

Expected impact

Potential slight upside pressure, but limited due to low transaction size.

Evidence & confidence

The purchase is under $20k and represents a tiny fraction of float, so market impact is likely minimal.

Market effects

Minor signal for biotech sector; no broad implications.

Limited to US biotech investors.

Negligible on a global scale.

Counterpoint

The purchase may be routine compensation rather than a strong endorsement of the company's prospects.

Key entities

  • enGene Therapeutics Inc.

    Biotech firm developing gene‑editing therapies, ticker ENGN.

  • Grossman William

    Interim Chief Medical Officer of ENGN.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ENGNHighAI 8/10

Engene stock maintains Outperform rating on bladder cancer data

Raymond James reiterated an Outperform rating and $4.00 price target on Engene Holdings (ENGN) after positive bladder cancer trial data. The stock is down 79% from its 52-week high but has a strong balance sheet. The FDA meeting feedback and trial results suggest potential approval by 2026. Other analysts also commented on the company's prospects.

$ENGNLow

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Corporate Presentation Non-Viral Genetic Medicine Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the mea